120 days ago
90 days ago
30 days ago
7 days ago
Clinical trial, phase 1
Clinical trial, phase 2
Clinical trial, phase 3
Clinical trial, phase 4
Consensus development conference
Consensus development conference, NIH
Controlled clinical trial
Corrected republished article
Randomized controlled trial
All infant: 0-23 mos
All child: 0-18 yrs
All adult: 19+ yrs
Newborn: birth-1 mo
Preschooler: 2-5 yrs
Adolescent: 13-18 yrs
Young adult: 19-24 yrs
Middle-aged: 45-64 yrs
Aged: 65+ yrs
Elderly: 80+ yrs
Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study.
117(8):1721-30 PMID 21061328
The aim of the current study was to catalog genomic and epigenomic abnormalities in newly diagnosed glioblastoma patients and determine the correlation among clinical, genetic, and epigenetic profiles and clinical outcome.
This study retrospectively included 68 consecutive patients who underwent surgical treatment and received standard radiotherapy with temozolomide (TMZ)-based chemotherapy. Of a total of 68 patients, 39 patients (57.4%) received interferon (IFN)-β in combination of TMZ.
The genetic and epigenetic alterations frequently observed were EGFR amplification (51.5%), TP53 mutation (33.8%), CDKN2A loss (32.4%), TP53 loss (16.2%), methylation of the MGMT promoter (33.8%) and IDH1 mutation (5.9%). Multivariate analysis revealed that methylated MGMT promoter and the combination of TMZ and IFN-β were independent prognostic factors associated with survival. The median survival time (MST) of the patients who received the combination of IFN-β and TMZ was significantly greater with 19.9 months as compared to the TMZ alone group (12.7 months). Notably, in even patients whose tumors had unmethylated MGMT promoter, the MST prolonged to 17.2 months when receiving TMZ with IFN-β, compared to 12.5 months in those receiving TMZ without IFN-β.
Taken together, addition of IFN-β for newly diagnosed primary GBM achieved a favorable outcome, particularly in patients with unmethylated MGMT promoter.
Copyright © 2010 American Cancer Society.
Version: za2963e q8za8 q8zbd q8zcc q8zd1 q8zef q8zfc q8zgd
Similar articles you may find interesting…
Carcinosarcoma arising in a patient with multiple cylindromas.
Am J Dermatopathol (2005)
27(1):21-6 PMID 15677972
Familial cylindromatosis (Brooke-Spiegler syndrome) is a rare autosomal dominant inherited disease characterized by the development of adnexal tumors, mostly cylindromas, but also trichoepitheliomas and spiradenomas. Malignant tumors may occur, usually with the features of a cylindrocarcinoma.The au...
Fine needle aspiration cytology in lesions of the nose, nasal cavity and paranasal sinuses.
Acta Cytol (2011)
55(2):135-41 PMID 21325797
Out of a total of 79,851 FNACs, 158 (0.2%) were from the sinonasal region. FNAC was non-diagnostic in 20 (12.6%) cases. Infective/inflammatory lesions comprised of 30 (19%) cases including non-specific inflammation (19), fungal infection (7), tuberculosis (2), actinomycosis (1) and filariasis (1). B...
High (nuclear) grade adnexal carcinoma with microcystic adnexal carcinoma-like structural features.
Am J Dermatopathol (2006)
28(4):346-51 PMID 16871041
We report a case of adnexal carcinoma with architectural features of MAC that displayed also marked nuclear pleomorphism and hyperchromasia with squamous pearl formation and a widespread strong p53 immunoreaction. The lesion behaved as a high-grade neoplasm with rapid growth, carcinosarcomatous meta...
Place any articles on Pubget into your Bookmark folder to read later, download citations, or send to a colleague. Create an account or sign in to create your bookmarks.
Pubget Updates sends you emails when Pubget finds new papers that match your search. Use Pubget Updates to get the latest articles for your specialty, written by a colleague, or published by your favorite journals.